Leerink Partnrs Has Strong Estimate for Bruker Q2 Earnings

Bruker Corporation (NASDAQ:BRKR) – Investment analysts at Leerink Partnrs upped their Q2 2025 earnings estimates for Bruker in a report released on Thursday, July 17th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings of $0.38 per share for the quarter, up from their prior forecast of $0.37. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Leerink Partnrs also issued estimates for Bruker’s Q3 2025 earnings at $0.64 EPS, Q4 2025 earnings at $0.93 EPS, Q3 2026 earnings at $0.68 EPS and Q4 2026 earnings at $0.99 EPS.

A number of other research analysts have also recently commented on BRKR. The Goldman Sachs Group reduced their target price on shares of Bruker from $50.00 to $45.00 and set a “neutral” rating on the stock in a research report on Thursday, May 8th. Wells Fargo & Company cut their price target on shares of Bruker from $75.00 to $60.00 and set an “overweight” rating on the stock in a report on Thursday, April 17th. Stifel Nicolaus lowered their target price on shares of Bruker from $57.00 to $48.00 and set a “hold” rating for the company in a research note on Thursday, May 8th. Barclays lowered their target price on shares of Bruker from $50.00 to $46.00 and set an “overweight” rating for the company in a research note on Thursday, May 8th. Finally, Bank of America lowered their price target on shares of Bruker from $61.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, June 26th. Six equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $52.89.

Bruker Price Performance

BRKR opened at $38.80 on Monday. The company has a quick ratio of 0.74, a current ratio of 1.57 and a debt-to-equity ratio of 1.13. Bruker has a 52-week low of $34.10 and a 52-week high of $72.94. The company has a 50 day moving average of $39.34 and a two-hundred day moving average of $44.58. The company has a market cap of $5.88 billion, a P/E ratio of 74.62, a P/E/G ratio of 2.40 and a beta of 1.18.

Bruker (NASDAQ:BRKR) last released its earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.01. Bruker had a net margin of 2.31% and a return on equity of 19.47%. The firm had revenue of $801.40 million during the quarter, compared to the consensus estimate of $763.83 million. During the same period in the previous year, the firm earned $0.53 earnings per share. Bruker’s revenue was up 11.0% compared to the same quarter last year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Monday, June 16th were issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.52%. The ex-dividend date was Monday, June 16th. Bruker’s payout ratio is 38.46%.

Insider Activity at Bruker

In other news, CEO Frank H. Laukien bought 2,608 shares of the firm’s stock in a transaction on Friday, June 6th. The stock was bought at an average cost of $38.36 per share, for a total transaction of $100,042.88. Following the completion of the acquisition, the chief executive officer directly owned 38,462,171 shares in the company, valued at $1,475,408,879.56. This represents a 0.01% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 27.30% of the stock is currently owned by insiders.

Institutional Trading of Bruker

A number of hedge funds have recently made changes to their positions in the stock. London Co. of Virginia lifted its position in shares of Bruker by 78.4% in the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company’s stock worth $245,820,000 after purchasing an additional 1,843,294 shares in the last quarter. Sculptor Capital LP raised its position in Bruker by 51.6% during the first quarter. Sculptor Capital LP now owns 2,598,438 shares of the medical research company’s stock valued at $108,459,000 after acquiring an additional 884,423 shares in the last quarter. Brown Advisory Inc. raised its position in Bruker by 18.9% during the first quarter. Brown Advisory Inc. now owns 2,410,137 shares of the medical research company’s stock valued at $100,599,000 after acquiring an additional 383,425 shares in the last quarter. Geode Capital Management LLC raised its position in Bruker by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 2,013,741 shares of the medical research company’s stock valued at $118,081,000 after acquiring an additional 20,273 shares in the last quarter. Finally, FIL Ltd raised its position in Bruker by 262.3% during the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company’s stock valued at $114,978,000 after acquiring an additional 1,420,102 shares in the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.